Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 24.02 as of 2026-09-10T20:00:02.000Z.
Consensus retrieved: 2026-09-10T03:48:36.960Z. This records retrieval, including cache reads, rather than vendor publication. A quote earlier than this retrieval cannot support current forward valuation.
Quote observation: 2026-09-10T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8233e5283909ab17bac4fe0d43cc0ba3aba61090fff26db7a4ef3d6a4b71faa0
Forward PE Ratio (24.02) = Close Price ($603.18) / Consensus Forward EPS ($25.11)
FORWARD PE RATIO
24.02
SECTOR MEDIAN · HEALTHCARE
19.77
median of 54 covered companies
CURRENT VS SECTOR MEDIAN
+21.50%
vs the sector median at left
Thermo Fisher Scientific Inc.
Market Cap
$224.15B
Forward PE Ratio
24.02
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Thermo Fisher Scientific Inc. (TMO) | $224.15B | 24.02 |
| Amgen Inc. (AMGN)vs › | $206.42B | N/A |
| AstraZeneca PLC (AZN)vs › | $247.58B | N/A |
| Novo Nordisk A/S (NVO)vs › | $195.43B | N/A |
| Gilead Sciences, Inc. (GILD)vs › | $179.79B | N/A |
| Abbott Laboratories (ABT)vs › | $178.87B | N/A |
| Pfizer Inc. (PFE)vs › | $157.59B | 9.30 |
| Danaher Corporation (DHR)vs › | $141.00B | 23.59 |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $130.60B | 27.45 |
| Bristol-Myers Squibb Company (BMY)vs › | $130.22B | N/A |
Trailing P/E
32.5
reported TTM EPS
Forward P/E
24.0
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $25.11 implies +35.1% EPS growth vs the reported trailing $18.59.
At today's $603.18 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $25.11 | $24.99 – $25.19 | 16 | 24.0x |
| 2027-12-31 | $27.40 | $26.38 – $28.95 | 16 | 22.0x |
| 2028-12-31 | $30.24 | $26.99 – $32.71 | 6 | 19.9x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
